WO2006060424A3 - Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible - Google Patents

Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible Download PDF

Info

Publication number
WO2006060424A3
WO2006060424A3 PCT/US2005/043190 US2005043190W WO2006060424A3 WO 2006060424 A3 WO2006060424 A3 WO 2006060424A3 US 2005043190 W US2005043190 W US 2005043190W WO 2006060424 A3 WO2006060424 A3 WO 2006060424A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
oxide synthase
inducible nitric
compounds
dimerization inhibitors
Prior art date
Application number
PCT/US2005/043190
Other languages
English (en)
Other versions
WO2006060424A2 (fr
Inventor
Timothy C Gahman
Hengyuan Lang
Mark R Herbert
Angelina M Thayer
Christian A Hassig
Stewart A Noble
Russell D Cousins
Hui Zhuang
Christopher R Santos
Xiaohong Chen
Original Assignee
Kalypsys Inc
Timothy C Gahman
Hengyuan Lang
Mark R Herbert
Angelina M Thayer
Christian A Hassig
Stewart A Noble
Russell D Cousins
Hui Zhuang
Christopher R Santos
Xiaohong Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc, Timothy C Gahman, Hengyuan Lang, Mark R Herbert, Angelina M Thayer, Christian A Hassig, Stewart A Noble, Russell D Cousins, Hui Zhuang, Christopher R Santos, Xiaohong Chen filed Critical Kalypsys Inc
Priority to EP05852447A priority Critical patent/EP1817030A2/fr
Priority to AU2005311985A priority patent/AU2005311985A1/en
Priority to BRPI0518096-1A priority patent/BRPI0518096A/pt
Priority to JP2007544442A priority patent/JP2008521908A/ja
Priority to CA002589433A priority patent/CA2589433A1/fr
Publication of WO2006060424A2 publication Critical patent/WO2006060424A2/fr
Publication of WO2006060424A3 publication Critical patent/WO2006060424A3/fr
Priority to IL183392A priority patent/IL183392A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés et des méthodes utiles comme inhibiteurs de l'oxyde nitrique synthase. Certains composés selon l'invention comprennent la formule structurelle suivante : (I) dans laquelle T, X et Y sont choisis indépendamment dans le groupe constitué de CR4, N, NW, S et O ; U est choisi dans le groupe constitué de CR10 et N ; V est choisi dans le groupe constitué de CR4 et N; W et W' sont indépendamment choisi dans le groupe constitué de CH2, CR7R8, NR9, O, N(O), S(O)q et C(O) ; n, m et p valent indépendamment un entier de 0 à 5 ; q vaut 0, 1 ou 2 ; et d'autres substituants sont tels que définis dans le descriptif. D'autres composés selon l'invention présentent des formules structurelles telles que définies dans le descriptif. L'invention concerne également des compositions pharmaceutiques comprenant les composés selon l'invention.
PCT/US2005/043190 2004-12-01 2005-11-28 Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible WO2006060424A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP05852447A EP1817030A2 (fr) 2004-12-01 2005-11-28 Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible
AU2005311985A AU2005311985A1 (en) 2004-12-01 2005-11-28 Inducible nitric oxide synthase dimerization inhibitors
BRPI0518096-1A BRPI0518096A (pt) 2004-12-01 2005-11-28 composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos
JP2007544442A JP2008521908A (ja) 2004-12-01 2005-11-28 誘導型一酸化窒素シンターゼ阻害剤
CA002589433A CA2589433A1 (fr) 2004-12-01 2005-11-28 Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible
IL183392A IL183392A0 (en) 2004-12-01 2007-05-24 Inducible nitric oxide synthase dimerization inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63197104P 2004-12-01 2004-12-01
US60/631,971 2004-12-01
US67200105P 2005-04-14 2005-04-14
US60/672,001 2005-04-14

Publications (2)

Publication Number Publication Date
WO2006060424A2 WO2006060424A2 (fr) 2006-06-08
WO2006060424A3 true WO2006060424A3 (fr) 2007-03-29

Family

ID=36215758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/043190 WO2006060424A2 (fr) 2004-12-01 2005-11-28 Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible

Country Status (11)

Country Link
US (1) US7825256B2 (fr)
EP (1) EP1817030A2 (fr)
JP (1) JP2008521908A (fr)
KR (1) KR20070084574A (fr)
AR (1) AR055287A1 (fr)
AU (1) AU2005311985A1 (fr)
BR (1) BRPI0518096A (fr)
CA (1) CA2589433A1 (fr)
IL (1) IL183392A0 (fr)
TW (1) TW200635587A (fr)
WO (1) WO2006060424A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070123572A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
BRPI0620526A2 (pt) * 2005-11-28 2011-11-16 Kalypsys Inc sal de acetato e método para alcançar um efeito em um paciente
US20080293942A1 (en) * 2005-11-28 2008-11-27 Cousins Russell D Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives
FR2903405B1 (fr) * 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
WO2008070447A2 (fr) * 2006-11-21 2008-06-12 Smithkline Beecham Corporation Composés anti-viraux
EP1939181A1 (fr) * 2006-12-27 2008-07-02 sanofi-aventis Carboxamides hétérocycliques et leur utilisation pour la stimulation de l'expression de la NO synthase
WO2008086176A2 (fr) * 2007-01-08 2008-07-17 Kalypsys, Inc. Préparation pharmaceutique topique comprenant un inhibiteur d'inos pour le traitement d'une maladie
EP2240021A4 (fr) * 2008-01-30 2011-08-17 Glaxosmithkline Llc Nouveaux inhibiteurs de seh et leur utilisation
JP2011510998A (ja) * 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびその使用
US8578892B2 (en) * 2008-06-13 2013-11-12 Air Products And Chemicals, Inc. Oxygen control system for oxygen enhanced combustion of solid fuels
US8478446B2 (en) 2008-06-13 2013-07-02 Air Products And Chemicals, Inc. Oxygen control system for oxygen enhanced combustion
JP2015180606A (ja) * 2012-08-01 2015-10-15 アステラス製薬株式会社 抗癌剤の併用による癌治療方法
CN106572988B (zh) 2014-04-08 2022-04-08 卫理公会医院 Inos抑制性组合物及其作为乳腺癌治疗剂的用途
WO2016007966A2 (fr) 2014-07-11 2016-01-14 Northwestern University Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale
JP6460382B2 (ja) * 2014-11-28 2019-01-30 株式会社豊田自動織機 飽和ヘテロ環含有化合物、並びにこれを用いた二次電池用電極及び二次電池、結着剤、蛍光物質
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
JP7153653B2 (ja) * 2017-02-14 2022-10-14 リサーチ トライアングル インスティテュート プロリン系神経ペプチドｆｆ受容体モジュレーター

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123319A2 (fr) * 1983-04-26 1984-10-31 Montedison S.p.A. 3-Azolyl-1,4-dicétones insaturées, fongicides
EP0175187A1 (fr) * 1984-09-15 1986-03-26 A. Nattermann & Cie. GmbH Dihydro-3,4 (1H)-pyridones-2 et (1H)-pyridones-2 contenant un groupe imidazole, procédé pour leur préparation et médicaments les contenant
WO1997015555A2 (fr) * 1995-10-25 1997-05-01 Schering Aktiengesellschaft Derives d'imidazole et utilisation comme inhibiteurs de synthase de monoxyde d'azote
WO1998000430A1 (fr) * 1996-06-27 1998-01-08 Schering Aktiengesellschaft Derives d'imidazol utiles comme inhibiteurs de la synthase de monoxyde d'azote
WO1998037079A1 (fr) * 1997-02-19 1998-08-27 Berlex Laboratories, Inc. Derives n-heterocycliques utiles en tant qu'inhibiteurs de la no synthetase
WO2001014371A1 (fr) * 1999-08-26 2001-03-01 Berlex Laboratories, Inc. Derives n-heterocycliques sous forme d'inhibiteurs oxyde nitrique synthase
WO2004069846A1 (fr) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, leur procede de production et leur utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US5874452A (en) * 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
SI1014966T1 (sl) 1996-05-31 2006-10-31 Allelix Neuroscience Inc Zdravilo za zdravljenje nevroloskih in nevripsihiatricnih bolezni
ID23510A (id) * 1997-06-27 2000-04-27 Bp Chem Int Ltd Proses polimerisasi
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US20030191279A1 (en) * 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6723743B1 (en) * 1999-09-28 2004-04-20 Neurogen Corporation High affinity small molecule C5a receptor modulators
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
FR2827286A1 (fr) 2001-07-11 2003-01-17 Aventis Cropscience Sa Nouveaux composes fongicides
US7365085B2 (en) 2002-03-27 2008-04-29 Smithkline Beecham Corporation Compounds and methods
WO2003084524A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
MXPA04009419A (es) 2002-03-29 2005-01-25 Neurogen Corp Nuevos aril imidazoles y compuestos relacionados como moduladores del receptor c5a.
WO2004014881A2 (fr) * 2002-08-09 2004-02-19 Astra Zeneca Ab Nouveaux composes
WO2004019986A1 (fr) 2002-08-29 2004-03-11 Schering Aktiengesellschaft Methodes permettant de traiter le syndrome de detresse respiratoire aigue
BRPI0620526A2 (pt) * 2005-11-28 2011-11-16 Kalypsys Inc sal de acetato e método para alcançar um efeito em um paciente

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123319A2 (fr) * 1983-04-26 1984-10-31 Montedison S.p.A. 3-Azolyl-1,4-dicétones insaturées, fongicides
EP0175187A1 (fr) * 1984-09-15 1986-03-26 A. Nattermann & Cie. GmbH Dihydro-3,4 (1H)-pyridones-2 et (1H)-pyridones-2 contenant un groupe imidazole, procédé pour leur préparation et médicaments les contenant
WO1997015555A2 (fr) * 1995-10-25 1997-05-01 Schering Aktiengesellschaft Derives d'imidazole et utilisation comme inhibiteurs de synthase de monoxyde d'azote
WO1998000430A1 (fr) * 1996-06-27 1998-01-08 Schering Aktiengesellschaft Derives d'imidazol utiles comme inhibiteurs de la synthase de monoxyde d'azote
WO1998037079A1 (fr) * 1997-02-19 1998-08-27 Berlex Laboratories, Inc. Derives n-heterocycliques utiles en tant qu'inhibiteurs de la no synthetase
WO2001014371A1 (fr) * 1999-08-26 2001-03-01 Berlex Laboratories, Inc. Derives n-heterocycliques sous forme d'inhibiteurs oxyde nitrique synthase
WO2004069846A1 (fr) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, leur procede de production et leur utilisation

Also Published As

Publication number Publication date
IL183392A0 (en) 2007-09-20
WO2006060424A2 (fr) 2006-06-08
JP2008521908A (ja) 2008-06-26
US20060116515A1 (en) 2006-06-01
US7825256B2 (en) 2010-11-02
CA2589433A1 (fr) 2006-06-08
TW200635587A (en) 2006-10-16
EP1817030A2 (fr) 2007-08-15
AU2005311985A1 (en) 2006-06-08
AR055287A1 (es) 2007-08-15
KR20070084574A (ko) 2007-08-24
BRPI0518096A (pt) 2008-10-28

Similar Documents

Publication Publication Date Title
WO2006060424A3 (fr) Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible
NO20091706L (no) Inhibitorer av hepatitt C virus
WO2004082822A3 (fr) Procedes permettant d'isoler la forme i cristalline de la 5-azacytidine
RS51136B (sr) Supstituisani pirolopiridini, kompozicije koje ih sadrže, postupak za njihovo dobijanje i upotreba
WO2007103550A3 (fr) Derives d'aminothiazole substitues presentant une activite anti-hcv
EA200401157A1 (ru) N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
NO20091704L (no) Inhibitorer av hepatitt C virus
NO20091707L (no) Inhibitorer av hepatitt C virus
WO2007056159A3 (fr) Derives d'hydrazone et utilisations de ceux-ci
NO20062185L (no) Hepatitt C virus-inhibitorer
WO2008030744A3 (fr) Inhibiteurs de c-met et leurs utilisations
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
WO2009025839A3 (fr) Inhibiteurs de phosphodiestérase 10
WO2012080284A3 (fr) Composés hétérocycliques azotés 6,6-condensés substitués et leurs utilisations
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
WO2008108380A3 (fr) Composés de pyrrole
NO20060963L (no) Nikotinamidderivater anvendelige som PDE4-inhibitorer
WO2007019191A3 (fr) Inhibiteurs de la thiazolopyrimidine kinase
WO2005005389A3 (fr) Derives de malonamide
WO2007081690A3 (fr) Inhibiteurs de protéine kinases
WO2008147812A3 (fr) Composés 4' substitués ayant une affinité de récepteur 5-ht6
MX2023002224A (es) Compuestos heterociclicos.
MY139454A (en) 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
WO2005011609A3 (fr) Composes tricycliques a base de triazolopurine et compositions pharmaceutiques contenant ces composes
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 183392

Country of ref document: IL

Ref document number: 2007544442

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580040524.2

Country of ref document: CN

Ref document number: 555403

Country of ref document: NZ

Ref document number: 2005311985

Country of ref document: AU

Ref document number: 2005852447

Country of ref document: EP

Ref document number: 2589433

Country of ref document: CA

Ref document number: 12007501114

Country of ref document: PH

Ref document number: 1890/KOLNP/2007

Country of ref document: IN

Ref document number: 1020077011898

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005311985

Country of ref document: AU

Date of ref document: 20051128

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005311985

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005852447

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0518096

Country of ref document: BR